Reversion of hair loss using factors comprised in compositions derived from stress-induced cells
A stress-induced cell factor composition addresses the limitations of existing hair loss treatments by providing a cell-free mixture that stimulates hair root regeneration and reverses hair loss effectively.
Patent Information
- Application Number
- PCT/EP2026/064222
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Existing treatments for hair loss and damaged hair roots, such as clinical drugs and hair transplantation, often fail to provide long-term results and can cause adverse side effects, while recent strategies like organoid architecture and tissue engineering lack a suitable microenvironment for hair root regeneration.
A composition comprising factors obtained by subjecting cells to stress, such as hypoxia, and collecting the supernatant under conditions that prevent contamination, to create a cell-free mixture for regenerating damaged hair roots and reversing hair loss.
The composition effectively stimulates hair root regeneration and reverses hair loss by providing essential factors like VEGF-C, PDGF-BB, and bFGF, enhancing hair growth and gene expression, without systemic side effects.
Smart Images

Figure 00000028_0000 
Figure 00000028_0001 
Figure 00000029_0000
Abstract
Description
[0001] New PCT-Patent Application
[0002] Machens Innovations Holding GmbH
[0003] Vossius Ref.: AJ1481 PCT
[0004] Reversion of hair loss using factors comprised in compositions derived from stress-induced cells
[0005] The present invention relates to a composition for use in a method of regenerating damaged hair roots and / or reverting hair loss comprising factors obtained or obtainable by a method comprising or consisting of (a) subjecting cells to stress; and (b) collecting the supernatant comprising factors produced by said cells when subjected to said stress under conditions that prevent contamination of said supernatant by pathogens and / or non-pathologic cells and / or parts of pathogens or non-pathogenic cells; and thereby obtaining said composition.
[0006] Hair follicles originate from the ectoderm and are associated with the skin. Besides their function in respect to hair morphogenesis and growth, hair follicles participate in physical protection, thermal insulation or sensory perception. Loss or damage of hair follicles impair the inherent skin function and hair growth and often lead to elimination of the hair cycle, resulting in permanent defective hair growth, hair loss and baldness. Traditionally, hair loss is treated by the application of clinical drugs, or hair transplantation, wherein the latter is often not maintained in the long term and involves a laborious, costly therapy. Clinical drugs, such as caffeine, finasteride or minoxidil are delivered by using nanomaterials, scaffolds or hydrogels. In case of finasteride and minoxidil also oral administration has been performed, which, however, is known to cause adverse side effects. Recent strategies also involve the use of organoid architecture and tissue engineering, which however are limited by the lack of a microenvironment able to replicate the physiological ensemble of connective tissue, blood vessel and immune cells and the key molecules required for hair root regeneration (Ji et al., 2021). With the high frequency of hair loss in both men and women across all races and the significant impact on the wellbeing and quality of life of individuals suffering from hair loss, a greater understanding of the complex hair cycle and hair growth processes is in high demand.
[0007] The growth of a hair follicle, i.e., the hair cycle, involves three phases: anagen (active growing about 90% of hair), catagen (regression, less than 10% of hair) and telogen (quiescence, 5%-10% of hair), wherein the last phase involves shedding of hair. Stem cells fuel the hair production transition between these cyclical phases of rest and activity. The regulation of the hair cycle is based on a complex interplay of multiple, incompletely understood endocrine, autocrine and paracrine signaling pathways. Thus, multiple factors inside and outside of hair follicles can influence the growth and cause damage to the hair follicle resulting in degenerated hair growth and hair loss (alopecia).
[0008] Alopecia is categorized in scarring or cicatricial alopecia and non-scarring or non-cicatricial alopecia. In scarring alopecia, the hair follicles are irreversibly destroyed due to presently unknown inflammationmechanisms. In non-scarring alopecia the hair cycle is altered, and hair follicles may be damaged or are dysfunctional due to various causes, such as increased expression of pro-inflammatory cytokines resulting in oxidative stress but also dysregulation of immune cells as it occurs in acquired autoimmune disorder (Pratt et al., 2017; Shimizu et al., 2022).
[0009] Generally, when stress is experienced, a homeostasis is being challenged. Psychological stress, which is mainly system stress, influences hormones, and the well-being of the subject experiencing stress. Physiological stress additionally also refers to local stress. Hair roots may be locally stressed by physical impact on the hair (pulling hair, or hair styling causing tension, traction, and local traumata) or systemically by oxidative stress. Oxidative stress impacts the condition of the hair fiber before and after emerging of the hair fiber from the epidermis. Sources of oxidative stress impacting the pre-emergent fiber include oxidative metabolism, smoking, UV radiation (UVR), inflammation from microbial, pollutant or irritant origins and oxidized scalp lipids, while those impacting the post-emergent fiber include again, UVR and chemical insults from oxidizing hair colorants and pollutants (Trueb, 2015, 2021). Despite having different causes, any type of stress which is sensed by the existing homeostasis, will trigger a response at molecular, cellular and systemic level to preserve the homeostasis and induce adaptation.
[0010] It is known that on cellular level the expression of proteins, which is regulated by feedback mechanisms and cascades, will adjust to a certain increase or decrease of protein expression in dependence to the stress or stimuli. Thus, the application of stress is helpful to drive the increase and production of certain biomolecules to answer specific research questions. The regulation of gene expression for hair root regeneration and morphogenesis however is still elusive and many of the key biomolecules and interactors are unknown. While the replication of an environment for regenerative hair roots is still under investigation, more general approaches are reported in the art that target general tissue regeneration with angiogenic factors. In these studies, the stress environment is replicated to understand the nature of the biomolecules involved in the process of tissue regeneration. Often hypoxia as the primary angiogenic stimulus is used.
[0011] Exposing cells to hypoxia to induce production of angiogenic factors has widely been investigated (Cheema et al. 2008; Namiki et al. 1995; Di et al. 2009). Furthermore, pre-conditioning cells (e.g., bone marrow stem cells) to hypoxia has been shown to increase their survival and angiogenic potency upon transplantation (Kubo et al. 2009). Cellular hypoxia-induced signaling could induce directional angiogenesis in vitro and in vivo (Hadjipanayi et al. 2010b). On the basis of this, an angiogenic therapy was developed that aims to deliver hypoxia-induced signaling without living cells (Hadjipanayi et al.
[0012] 2011 ; WO / 2009 / 136173), wherein hypoxia-induced signaling can be delivered in vivo, on-demand, without relying on ongoing production of factors by living cells. However, this therapy still faces certain limitations, such as being highly invasive, bearing common complications of surgery (e.g., bleeding, infection, thrombosis), and requiring multiple applications to provide angiogenic factors (e.g., VEGF) which are known to have a short half-life (Cao and Mooney 2007), and the lack to fully replicate the physiological environment wherein different factors are expressed at different times.In a patent published as EP2809333, stimulation of angiogenesis has been achieved by using stress (e.g., hypoxia) on cells in a first carrier, resulting in the secretion of growth factors which are captured in a second carrier, which is a scaffold free from cells and contaminants. The collection of said factors is achieved by using a device comprising the first carrier, second carrier and means of subjecting the cells in the first carrierto stress Application of the obtained mixture of factors described a way to improve wound tissue healing and treating or preventing tissue damage. Providing damaged tissue with one or more compositions as described in EP2809333 has been shown to be suitable to replace the missing factors at the site of tissue damage such that healing proceeds further. The tissue damage treated or prevented is more specifically a wound caused by radiation, ulcers, incisions, lacerations, abrasions, burns or post-wound or post-grafting ischemic tissue. Accordingly, the disorders which are described to be treated in the prior art by factors derived from hypoxia-treated cells, are associated with diseases of the vascular system, cartilage repair, muscle repair and growth, bone and tendon healing, and nerve regeneration.
[0013] In summary, methods in the prior art describe the advantages of the utilization of products obtained by stress (e.g. hypoxia) induced cells which however are unrelated to the treatment of hair loss. Recent strategies and treatments to treat damaged hair roots as described above do not provide a long-term result and / or require large personnel or financial investments. Clinical drugs which are delivered in cremes and lotions on the affected hair defective area provide a simple, low-cost treatment which however often cause side effects (such as irritations by the active compounds in those drug compositions) or a slow and unsatisfying hair growth.
[0014] In view of the prior art as described above the technical problem underlying the present invention can be seen in the provision of novel means and methods for hair root regeneration and reversion of hair loss. The technical problem is solved by the embodiments of the present invention.
[0015] Accordingly, the present invention relates in a first aspect to a composition for use in a method of regenerating damaged hair roots and / or reverting hair loss comprising factors obtained or obtainable by a method comprising or consisting of (a) subjecting cells to stress; and (b) collecting the supernatant comprising factors produced by said cells when subjected to said stress under conditions that prevent contamination of said supernatant by pathogens and / or non-pathologic cells and / or parts of pathogens or non-pathogenic cells; and thereby obtaining said composition.
[0016] As used herein, the term “hair loss” refers to the deficiency of hair growth and / or hair shedding resulting in a partial or complete loss of hair. In otherterms, a subject having hairloss experiences a state wherein hair is defective at a site where hair should normally be present. The term “hair loss” particularly refers to the loss of hair of the scalp and is associated with the damage of the hair roots.
[0017] The term “factor” is well known in the art and refers generally to any chemical species produced by a cell when, for example, subjected to stress. In a more specific sense, a factor refers to any protein associated with a regulatory function in the cell, preferably a cytokine or growth factor. The identity of certain factors produced by cells when subjected to stress is also apparent from the examples enclosedherewith. These factors include VEGF-C, PDGF-BB and bFGF (In vitro comparison of lymphangiogenic potential of hypoxia preconditioned serum (HPS) and platelet-rich plasma (PRP); Jiang J et al. Int J Mol Sci 2023: 24(3) 1961), TGF-beta1 , IGF-1 , bFGF, PDGF-BB, G-CSF and Leptin (Hypoxia-preconditioned serum (HPS) promotes proliferation and chondrogenic phenotype of chondrocytes in vitro; Jiang J et al. Int J Mol Sci 2023: 24 (13): 10441) as well as VEGF-A and EGF (Moog P et al. Int J Mol Sci 2023 (24 (6): 5485). These factors are preferably comprised in said composition.
[0018] Without wanting to be bound by theory, it is understood that the presence of these factors leads to the activation of transcription factors such as RELA, NFKB1 , JUN, FOS, STAT3, HIF1A and EPAS1 , which was e.g., demonstrated in Figure 12.
[0019] As used herein the term “conditions that prevent contamination of said supernatant by pathogen and / or non-pathogenic cells and / or parts of pathogens or non-pathogenic cells” relates to conditions excluding the cells subjected to stress or parts thereof, and / or exterior contaminants in the supernatant and accordingly in the composition. Means and methods to achieve such conditions are known in the art, including, for example sterile filtration using one or more filter(s) or diffusion through one or more membrane(s) of particular pore size(s) or a combination thereof. The means and methods for achieving conditions that prevent contamination also refer to the use of specific binding or inhibitory agents that exclude said contaminants by specific interaction. For example, the removal and / or inhibition of certain factors, such as inflammatory cytokines, matrix metalloproteinases and / or cellular metabolic products, may be desirable. This could be achieved for example with cytokine neutralizing antibodies (e.g., anti-TNFa monoclonal antibody), cytokine receptors (e.g., TNF-binding receptor; Etanercept) or enzyme inhibitors, in particular protease inhibitors (e.g., Tissue Inhibitors of Metalloproteinases; TIMP1, TIMP2, TIMP3, TIMP4.
[0020] It is understood that step (b) is performed under conditions that prevent contamination by pathogens and / or non-pathologic cells and / or parts of pathogens or non-pathogenic cells in a preferably one-step setup. Such setup provides forthe preparing of said composition, preferably without any need for further steps such as separation, filtration, centrifugation, or other means of purification.
[0021] The term “pathogen” as used herein refers to any pathogenic microorganism or substances derived from such pathogenic microorganisms. The term “non-pathogenic cell” refers primarily to the cells subjected to stress, which are excluded from the supernatants. As used herein, the term “parts of cells” refers to parts of the cell membrane, organelles and other cell components as well as certain biomolecules counteracting the regenerative character of the factors in the composition to be obtained. It is understood that parts of pathogens and / or non-pathogenic cells of a size smaller than the size of the applied filter or biomolecules which are not bound to a specific agent as described above, such as nucleotides, may not be excluded from the supernatant and obtained composition. The skilled person may choose the pore size of the filter and specific agents to bind certain biomolecules and excludes certain contaminants in accordance with criteria used in the art. For example, the parts of pathogens and / or non-pathogenic cells excluded by the filter are larger than 1 nm, preferably larger than 0.22 pm.
[0022] In case the method of obtaining said factors “comprises” steps a) and b), the supernatant comprisingthe factors may be further processed to formulate a therapeutic or cosmetic composition.
[0023] In a preferred embodiment of the first aspect, the conditions that prevent contamination comprise one or more filter(s), preferably one or more nano-porous filter(s), preferably with a pore width of 1 to 1000 nm, more preferably 0.22 pm. More than one filter may be used in an array of filters, preferably with decreasing pore size, wherein the filter with the smallest pore size is facing the composition to be obtained.
[0024] The term “composition”, as used herein, is free of the cells used in step (a) or any other contaminants, which is ensured by the conditions as described above. The composition comprises the factors secreted by the stressed cells in step (a) and may thus be a composition which provides similar conditions (such as pH, temperature, salt concentration) like the physiological conditions to ensure that the collected factors are present in their native and functional state. It is preferred that the composition is a liquid composition, such as derived / processed from a culture medium. It is particularly preferred that the substance is a gel or sol-gel. In this regard, it is understood that the obtained composition may be further converted in additional steps by additional constituents capable of forming gels or sol-gels.
[0025] As used herein the term “stress” relates to any condition that deviates from the conditions a given cell is subjected to when present in a homeostatic state without external disturbances affecting growth or function. Stress is established in the art in relation to living cells and may be triggered by subjecting cells to a stimulus, i.e., a stimulus that challenges homeostasis of said cells. Non-limiting examples for such stimuli are hypoxia, mechanical stress and electric impulses. As described above, “stress” refers to the challenge of a homeostasis, which results in a response of the stressed subject (e.g., a cellular response in case of cells) to preserve homeostasis and induce adaptation to said stress.
[0026] The term “cellular response” refers more specifically to a change in the expression pattern of peptidic and / or proteinaceous factors and may change over time. Cells subjected to stress provide a cellular response which includes the production, preferably the secretion of factors, wherein the secretion of factors is achieved by active secretion as well as passive diffusion.
[0027] In the present invention, the inventors utilized the cellular response to stressed cells, in particular hypoxia induced blood cells. The obtained hypoxia preconditioned serum (HPS) has been used to investigate the effect of factors collected from stressed cells on dermal papilla cells. Dermal papilla cells are those cells which are associated with hair root regeneration, hair cycling and hair morphogenesis in hair follicles.
[0028] The term “hypoxia preconditioned serum”, as used herein, and further abbreviated as “HPS” is a composition in accordance with the present invention, wherein blood cells have been stressed using hypoxic conditions. Means and methods to induce hypoxia are known in the art and are described in this specification elsewhere.The effects of HPS having a concentration of 1 % or 40% on dermal papilla cells has been demonstrated in the Examples 2 and 3, wherein the higher dose of 40% HPS stimulates proliferation better than lower doses. On the other hand, the gene expression of genes associated with hair morphogenesis and / or hair growth are increased in low (1%) as well as high doses of HPS (40%) depending on the particular gene. Genes which expression is increased after treatment with low doses of HPS comprise VEGFa. Genes which expression is increased after treatment with high doses of HPS comprise VEGFa.
[0029] In another preferred embodiment of the first aspect, the subjecting to stress is effected by exposing said cells to (i) hypoxia; (ii) mechanical stress; and / or (iii) electric stimulation.
[0030] The term “hypoxia” is known in the art and refers to the condition of lower oxygen in comparison to the partial pressure prevailing in normal air (about 21% (v / v) O2; (v / v) indicating volume percentage. Preferably, hypoxic conditions are established at oxygen levels between 0 and 10% (v / v) O2 and / or after additions of a chemical inducer of hypoxia, such as C0CI2. As is shown in the appended examples, hypoxic stress is most preferred.
[0031] As used herein, the term “mechanical stress” refers preferably to compressive, tensile, shear and / or hydrostatic stress. The skilled person is aware of methods to exert mechanical stress.
[0032] Electrical stimulation can be effected with certain parameter settings, such as a frequency of 1 to 20 Hz for 30 to 60 min, preferably the electric field strength is between 1 mV / mm and 1 kV / mm.
[0033] Certain conditions of stress, such as electric stimulation or mechanical stimulation may cause cells to be become leaky, which leakiness may entail that factors produced by the cells are set free.
[0034] In another preferred embodiment of the first aspect, the cells are blood cells or adipose tissue-derived stromal cells.
[0035] The term “blood cells” herein relates to the cells present in a sample of whole blood, preferably peripheral venous blood. Accordingly, the method for the preparation of the composition for use in a method of regenerating damaged hair roots and / or reverting hair loss comprising factors preferably comprises (a) subjecting peripheral venous blood to stress; and (b) collecting the supernatant comprising factors produced by said peripheral venous blood when subjected to said stress under conditions that prevent contamination of said supernatant by pathogens and / or non-pathologic cells and / or parts of pathogens or non-pathogenic cells; and thereby obtaining said composition.
[0036] The advantages of using such cells are the facilitated harvesting procedures from individuals and the relatively low technical costs for procurement of the relevant factors. Also, an upscaling of harvesting is possible through application of the harvesting procedure in large animal models like mini-pigs. The inventors have shown that the amount and type of harvested factors in mini-pigs is very similar to harvested factor amounts in humans (Hypoxia-preconditioned serum hydrogel (HPS-H) accelerates dermal regeneration in a porcine wound model; Jiang J et al. Gels 2024, 10, 748).As has been shown in the appended examples, blood cells are most preferred. In this context, particularly blood cells that have been treated with hypoxic stress are preferred. Accordingly, in a most preferred embodiment of the first or second aspect, the cell-free composition obtained by subjecting cells to stress is hypoxia-preconditioned serum (HPS).
[0037] In an alternative preferred embodiment of the first aspect the cells are autologous, allogeneic or xenogeneic (iv) fibroblasts; bone-marrow derived stromal cells; skeletal, smooth or cardiac muscle cells; epithelial cells; or adult stem cells; (v) myoblasts; osteocytes; osteoblasts; osteoclasts; chondrocytes; skeletal, smooth or cardiac muscle cells; dermal, tendon or cardiac fibroblasts; endothelial cells; or adult stem cells, or (vi) nerve cells; glial cells; skeletal, smooth or cardiac muscle cells; fibroblasts; osteocytes; osteoblasts; osteoclasts; chondrocytes; or adult stem cells including neural stem cells.
[0038] In another preferred embodiment of the first aspect of the present invention, wherein said cells are comprised in at least one first carrier and said collecting is effected by means of at least one second carrier which second carrier(s) are concomitantly present with and spatially distinct from the first carrier(s); and wherein first carrier and second carrier are positioned such that factors secreted by said cells when subjected to stress are collected in said second carrier, wherein at least one filter is positioned between said first and second carrier which prevents any cells or parts of cells and pathogens present in (any of) said first carrier(s) from entering into said second carrier.
[0039] The term “at least one first carrier” as used herein, refers to a substance that comprises cells, the cells being held together by endogenously produced molecules and thus is, but not required to be, free of any exogenously added substances or prepared material. In one embodiment, the materials of the first carrier (and / or of the second carrier) are chosen such that cells do not leave the first carrier and / or are not capable of entering to the second carrier. An option for the first carrier is a matrix wherein the cells are embedded and prevented from escaping. A preferred example of a first carrier is a syringe. A different example is a glass, acrylic glass or plastic carrier, closed at the bottom and reversibly opened at the top with a connection to the second carrier configured to allow the factors to pass into the second carrier but to retain the cells in the first carrier. Means of preventing entry of cells into the second carrier are disclosed above as means ensuring “conditions that prevent contamination.”
[0040] In a further preferred embodiment according to the first aspect, (a) at least one of the carriers or at least one of the first carrier(s) and the second carriers) or all carriers comprise one or more of (i) proteins, preferred proteins being collagen, fibrin, elastin and fibronectin; (ii) polysaccharides, preferred polysaccharides being chitin, alginate and cellulose; (iii) glycosaminoglycans, preferred glycosaminoglycans being chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin sulfate, heparan sulfate and hyaluronic acid; (iv) synthetic polymers, preferred synthetic polymers being polyglycolic acid, polylactic co-glycolic acid, polylactic acid or polycaprolactone, polystyrene and polyethylene terephtalate; (v) de-cellularised native tissue, preferred native tissues being dermis, small intestinal submucosa and bladder submucosa; and / or (vi) inorganic material, preferably calciumphosphate ceramics, alumina ceramics, zirconia ceramics, nitride ceramics, carbon nanotubes and metals selected from or alloys comprising titanium, tantalum, iron, magnesium, cobalt or chromium; (b) at least one of the carriers or at least one of the first carrier(s) and the second carriers) or all carriers are selected from gel; sponge; mesh; microparticles; nanoparticles; microfibers; nanofibers; preferably electrospun microfibers or nanofibers; and nanotubes; (c) said first carrier or at least one of said first carrier(s) furthermore comprises an electric conductor; (d) said first carrier or (at least one of) said first carrier(s) is / are selected from cell sheet(s) and split-thickness or full-thickness skin graft(s), said graft(s) and cell sheet(s) preferably being autologous; and / or (e) said second carrier is selected from cream, emollient or ointment.
[0041] In a most preferred embodiment, the cells are mammalian blood cells, such as blood cells comprised in whole blood, preferably peripheral venous blood and the stress is hypoxic stress, and the conditions that prevent contamination of said supernatant by pathogens and / or non-pathologic cells and / or parts of pathogens or non-pathogenic cells are achieved by the blood cells being comprised in a first carrier being a syringe and filtering the blood serum through a sterile filter preferably having a pore width of 0.22 pm. The factors comprised in the cell-free composition obtained in this manner are understood to be VEGF-C, PDGF-BB, bFGF, TGF-beta1 , IGF-1 , bFGF, PDGF-BB, G-CSF, Leptin as well as VEGF-A and EGF.
[0042] In an alternative most preferred embodiment, the cells are blood cells, preferably human blood cells, such as blood cells comprised in whole blood, preferably peripheral venous blood and the stress is hypoxic stress, and the conditions that prevent contamination of said supernatant by pathogens and / or non-pathologic cells and / or parts of pathogens or non-pathogenic cells are achieved by the blood cells being comprised in a first carrier being a syringe and filtering the blood serum through a sterile filter preferably having a pore width of 0.22 pm. The factors comprised in the cell-free composition obtained in this manner are understood to be VEGF-C, PDGF-BB, bFGF, TGF-beta1 , IGF-1 , bFGF, PDGF-BB, G-CSF, Leptin as well as VEGF-A and EGF. The resulting cell-free composition is used inside a pharmaceutical composition at a 40% concentration with the pharmaceutical composition further comprising one or more pharmaceutical carrier(s), diluent(s) or excipient(s). The pharmaceutical composition is topically applied for therapeutic or cosmetic regeneration of hair roots and preferably additionally comprises erythropoietin (EPO).
[0043] In another alternative most preferred embodiment, the cells are blood cells, such as blood cells comprised in whole blood, preferably peripheral venous blood and the stress is hypoxic stress, and the conditions that prevent contamination of said supernatant by pathogens and / or non-pathologic cells and / or parts of pathogens or non-pathogenic cells are achieved by the blood cells being comprised in a first carrier comprising synthetic polymers. The factors comprised in the cell-free composition obtained in this manner are understood to be VEGF-C, PDGF-BB, bFGF, TGF-beta1 , IGF-1 , bFGF, PDGF-BB, G-CSF, Leptin as well as VEGF-A and EGF. The resulting cell-free composition is topically applied for therapeutic or cosmetic regeneration of hair roots and preferably additionally comprises erythropoietin (EPO).The term “at least one second carrier”, as used herein on the other hand is free from cells at the beginning and remains owing to its spatial distinctness from the first carrier. The at least one second carrier is used for the purpose of collecting the factors secreted by said cells subjected to stress as contained in the first carrier. It is furthermore important that said first and second carriers are concomitantly present at least during step (b) and preferably during both steps (a) and (b).
[0044] By using more than one second carrier it is possible to separate the total factor load generated by the cells in said first carrier(s) into a plurality of smaller doses. Using a plurality of second carriers can produce different compositions, in this case preferably in conjunction with one first carrier. The obtained compositions may differ with regard to factor composition and / or factor concentration. This may be achieved, for example, by exposing each second carrier for different time periods of stress, for example, four, eight or twelve days. Each different composition obtained after a certain amount of time may comprise a distinct variety of factors. Such different compositions may be administered once or several times in a distinct sequence of administration stages / steps. The administration of the composition in several stages / steps, i.e., a certain sequence, may be used for example to evaluate allergic reactions. In a first stage a second carrier may be used which has been concomitantly present with said first carrier for a short period of time. Said administration may be followed with (a) second (or further) second carrier(s) which has / have been conditioned, i.e., kept concomitantly present with the first carrier for a longer period of time. Second carriers may also be replaced, i.e., in a first step a particular second carrier may be concomitantly present with said first carrier for a given period of time, followed by removal of the second carrier.
[0045] The “device configured to allow the passage of said factors and prevent passage of said cells” is understood as to relate to a device effecting conditions excluding the cells subjected to stress or parts thereof, pathogens and / or exterior contaminants to pass through the device into the supernatant and accordingly in the composition. Means and methods to achieve such conditions are known in the art, including, for example sterile filtration using one or more filter(s) or diffusion through one or more membrane(s) of particular pore size(s) or a combination thereof. The means and methods for achieving conditions that prevent contamination also refer to the use of specific binding or inhibitory agents that exclude said contaminants by specific interaction. For example, the removal and / or inhibition of certain factors, such as inflammatory cytokines, matrix metalloproteinases and / or cellular metabolic products, may be desirable. This can be achieved for example with cytokine neutralizing antibodies (e.g., anti-TNFa monoclonal antibody), cytokine receptors (e.g., TNF-binding receptor; Etanercept) or enzyme inhibitors, in particular protease inhibitors (e.g., Tissue Inhibitors of Metalloproteinases; TIMP1, TIMP2, TIMP3, TIMP4).
[0046] Another alternative to obtain several factor mixtures is envisaged in the repetition of the steps (a) and (b). Each collected factor mixture is representative of the state of said cells at the given point in time or period of time, the given point in time or beginning of said period of time being separated by defined time span from the beginning of the exposal to stress.Thus, in another preferred embodiment of the first aspect, step (a) or step (b) are repeated two or more times.
[0047] The repetition of steps (a) or (b) also allows for the collection of a higher concentration of factors in a composition.
[0048] In another preferred embodiment of the first aspect, the cells are mammalian cells.
[0049] In a more preferred embodiment of the above embodiment, the mammalian cells are human or porcine cells.
[0050] The usage of porcine cells has been studied in experiments by the inventors and enables the obtention of compositions having factors which are like those obtained when using human cells (Hypoxia-preconditioned serum hydrogel (HPS-H) accelerates dermal regeneration in a porcine wound model; Jiang J et al. Gels 2024, 10, 748). The production of compositions comprising factors for regenerating damaged hair roots using porcine cells indicates the possibility to use the present invention on industrial scale.
[0051] In another preferred embodiment of the first aspect, the composition further comprises erythropoietin (EPO).
[0052] Erythropoietin is commonly known as EPO and well described in the field. The protein is particularly important for synthesizing erythrocytes (erythropoiesis) in the body. It is known that recombinant human erythropoietin (rh EPO) can also trigger other auto-regenerative effects in the body in combination with other factors, such as growth factors and cytokines. However, it remains elusive which specific additional factors are required to trigger those auto-regenerative effects.
[0053] As disclosed above, the factors comprised in the composition of the first aspect of the invention can improve regeneration, such as hair root regeneration and hair loss reversion. The combination of the factors as obtained in the composition as defined in the first aspect, and EPO is considered, without wishing to be bound by a specific theory to further provide auto-regenerative effects and thus further improvement of regeneration of damaged hair roots and reversion of hair loss.
[0054] The regeneration of damaged hair roots is understood to help recovering hair loss, which can be caused by a disease or disorder.
[0055] Accordingly, in another preferred embodiment the regeneration of damaged hair roots is a therapeutical regeneration.Hair loss is also associated for example with age-dependent conditions, which cause the weakening of hair roots, leading to unwanted shedding of hair.
[0056] Thus, in an alternative preferred embodiment of the first aspect, the regeneration of damaged hair roots is a cosmetic regeneration.
[0057] In a second aspect, the present invention refers to a use of the composition as defined the first aspect of the present invention for cosmetic regeneration of damaged hair roots.
[0058] The definitions and preferred embodiments of the first aspect of the invention apply mutatis mutandis to the second aspect of the invention as far a being amenable therewith.
[0059] The composition according to the first or second aspect is to be administered to the subject suffering from damaged hair root and / or hair loss at the site of the damaged hair roots and / or on the area wherein hair growth is defective, but is normally expected (e.g., on the scalp). Thus, the administration routes for achieving therapeutical or cosmetic regeneration in respect to the first aspect or for the use for cosmetic regeneration of damaged hair roots of the second aspect comprises dermal administration routes.
[0060] Accordingly, in another preferred embodiment of the first or second aspect, the composition is to be administered topically or transdermally to a subject in a therapeutically or cosmetically effective amount.
[0061] The composition of the first aspect of the present invention as described above in a liquid, a gel or a solgel state, may have distinct viscosities. High viscosity in this context refers to such viscosities which, upon administration of said composition, ensure that said composition remains at the site of administration. The viscosity is preferably higher than that of water (1.0016 mPa*s, at 20°C) under the same conditions. Preferably, and in many instances related to said topical administration, the compositions according to the present invention provide for the controlled administration at a certain area such as at a certain area for a specific amount of time. Non-limiting examples of means for administration are ointments, creams, lotions, and gels.
[0062] A liquid state of the composition of the first aspect of the present invention with low viscosity, comparable to that of water may also be used for topical administration, and is preferably absorbed quickly by the skin area on which it has been applied, into the skin layer where hair roots are located.
[0063] The skin is a multilayered organ of mammals, wherein from the outside the upper layers constitute the epidermis, which is composed of two mayor layers (“stratum corneum” and “viable epidermis”) underlying this is the dermis which is on top of the subcutaneous fat.
[0064] The delivery through (the outer layer of) the skin, e.g., by absorption into the deeper skin layers, is a form of a passing through the skin and thus understood to be comprised in the term “transdermal delivery.” Since regenerative factors are particularly desired for the damaged hair roots, which are located in the epidermis and dermis of the skin, a transdermal delivery, is preferably considered.Additional means may help to ensure delivery to the hair roots. Particularly preferred is the additional usage of means that help penetration of the skin fortransdermal delivery, such as needle rollers or micro needles.
[0065] Absorption by the skin can also result in an undesired systemic absorption, if the active compound of the composition is absorbed in a way that it enters the patient’s systemic circulation. The skilled person is aware of the physiochemical properties of the composition that allow absorption into the epidermal and deeper skin layers while preventing or minimizing entry into the systemic circulation, which provides the functional blood supply to all body tissue (see, e.g., Alkilani et al., 2015). Prevention of the composition in entering the systemic circulation of the patient is desired to prevent systemic toxicity and / or undesirable side-effects caused by any compound of the composition. Other administration routes particularly associated with entry of a drug into the patient’s blood system, such as intravenous, oral, parenteral or pulmonary administration, are not comprised in the administration routes used for the present invention.
[0066] As described above, hair loss may be reversed by a composition of the first aspect for therapeutic or cosmetic regeneration. The therapeutical effective amount is determined by the skilled physician and clinical factors. As well known in the medical arts, dosages for any one patient depends upon many factors, including the patient’s size, body surface area, age, the compound to be administered, sex, time and route of administration, general health and other drugs being administered concurrently. The therapeutically effective amount will readily be determined by routine experimentation and is within the skills and judgement of the clinician or physician.
[0067] The cosmetic effective amount is determined by the cosmetician or is in accordance with the manufacturer’s instructions as described for example on the label or leaflet.
[0068] Generally, the regimen as a regular administration of the composition should be in the range of 1pg to 5g units per day. However, a more preferred dosage might be in the range of 0.01 mg to 100 mg, even more preferably 0.5 to 50 mg and most preferably 0.5 mg to 10 mg per day.
[0069] The concentration of the composition to be administered relies on the skilled person’s knowledge and data disclosed in the examples. Firstly, the optimal working conditions have been determined for hypoxia preconditioned serum (HPS) as described in Example 1 in the preliminary experiment 2, wherein 1% and 40% concentrations of HPS have been particularly optimal for incubation with dermal papilla cells (see. Fig. 1B). In a second experiment, the effects of HPS in the concentrations as determined in Fig.
[0070] 1B, on the migration and proliferation of dermal papilla cells were investigated (Example 2). The quantification (Fig. 2C) and images (Fig. 2A, B) show a better stimulating effect of higher concentrations (40%) of HPS on the cell proliferation and migration in comparison to commercially available compounds and platelet-rich plasma (PRP), a blood derived product.
[0071] Platelet-rich plasma, like HPS, is considered a blood product since it is derived from blood cells. In contrast to HPS, PRP has not been obtained from blood cells that have been subjected to external stress, but from the patient’s blood. To produce autologous PRP, PRP from the patient’s own blood, ablood sample is taken and concentrated (e.g., by centrifugation) by separating PRP from red and white blood cells.
[0072] The proliferation and migration of dermal papilla cells after treatment with HPS, PRP or commercially available compounds is shown in Fig. 2 B. The images in Fig. 2 B indicate a similar effect of PRP and HPS on cell proliferation, which however is not the case in respect to hair growth specific effects. Genes which are associated with hair growth and morphogenesis were investigated and their expression compared after treatment with different doses of HPS, PRP and commercially available compounds in Example 3. The effects of HPS in low (1% and additionally 10%) or high (40%) doses on the gene expression of hair growth associated genes are shown in Fig. 3. It is observable that the gene expression of some genes, e.g., versican, is increased after treatment with low doses of HPS, while others, e.g., VEGFa, show an increased expression after treatment with high doses of HPS (Fig. 3). In both cases, the gene expression after treatment with HPS is higher than after treatment with PRP, indicating increased stimulating effects of HPS on hair growth specific genes and thus regeneration of hair roots.
[0073] In a more preferred embodiment of the above preferred embodiment of the first aspect, the therapeutically effective amount to be administered is between 1% and 40%. Most preferably, the therapeutically effective amount to be administered is about 40%.
[0074] Pharmaceutical compositions of the invention preferably comprise a pharmaceutically acceptable carrier, diluent or excipient. The term "pharmaceutically acceptable carrier” refers to a carrier that can be administered to a subject with the pharmaceutical composition of the present invention when administered in a dose sufficient to deliver a therapeutic amount of the compound, without destroying its pharmacological activity and without being toxic to the recipient. The term “diluent” refers to a carrier which is specifically added to increase the volume or mass of a dosage form without altering the drug’s pharmacological activity and without being toxic to the recipient. An example of a pharmaceutically acceptable diluent is water.
[0075] The term "excipient", as used herein, refers to an inert constituent of a pharmaceutical composition, which imparts a beneficial physical property to a formulation such as increased protein stability and / or decreased viscosity. An “excipient” can be used as a vehicle, preservative, binder or stabilizing agent for drugs.
[0076] By “pharmaceutically acceptable carrier, diluent or excipient” is meant a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type (see also Handbook of Pharmaceutical Excipients 6ed. 2010, Published by the Pharmaceutical Press). Examples of suitable pharmaceutical carriers and excipients are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil / water emulsions, various types of wetting agents, sterile solutions, organic solvents including DMSO etc. Compositions comprising such carriers or excipients can be formulated by well-known conventional methods. The pharmaceutical composition may be administered, for example, parenterally, such as subcutaneously, intravenously, intramuscularly, intraperitoneally, transdermally, locally or topically to the skin. The pharmaceutical composition ispreferably administered topically ortransdermally to a subject.
[0077] Accordingly, the therapeutically effective amount refers to the share of the pharmaceutically active ingredient, i.e., the composition comprising hair-growth inducing factors obtainable by the method outlined in the first aspect in relation to the added carrier(s) and / or excipient(s). In the example of HPS, a therapeutically effective amount of 40% means that the composition comprises 40% HPS and 60% other components, such as pharmaceutically effective carrier(s) or excipient(s). It is herein to be understood that the carrier preferably relates to a pharmaceutically acceptable carrier or excipient. The same applies to the cosmetically effective amount.
[0078] The therapeutically effective amount to be administered is defined as a concentration of at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35% or 40%. Preferably the concentration is 1%, 10% or 40%, most preferably the concentration is 40%. In an alternative embodiment, the therapeutically effective amount to be administered is 100%.
[0079] In an alternative more preferred embodiment of the above preferred embodiment of the first aspect or second aspect the cosmetically effective amount to be administered is between 1% and 40%.
[0080] The cosmetically effective amount to be administered is defined as a concentration of at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, 30%, 35% or 40%. Preferably the concentration is 1%, 10% or 40%, most preferably the concentration is 40%. In an alternative embodiment, the cosmetically effective amount to be administered is 100%.
[0081] It is also envisaged that in another preferred embodiment the composition of the first aspect may be administered in combination with a pharmaceutically acceptable carrier or an excipient.
[0082] In a preferred embodiment of the first or second aspect of the present invention in respect to therapeutical regeneration and / or administration, the damaged hair root and / or hair loss is associated with physical or psychological stress; hormonal dysfunctions or alterations; infectious diseases; autoimmune diseases; and / or the hair loss is medication induced, preferably the hair loss is associated with alopecia, most preferably the alopecia is alopecia areata.
[0083] As used herein, and in accordance with the description above, the term “alopecia” refers to scarring and non-scarring alopecia, wherein non-scarring alopecia also comprises the common autoimmune condition “alopecia areata”. As described above, in alopecia hair follicles are irreversibly destroyed (scarring alopecia) or damaged and dysfunctional (non-scarring alopecia) causing hair loss from part of the head or body of a patient, typically in circular patches for alopecia areata on the head of the patient, wherein the severity of hair loss can vary. Further symptoms include male-or female-pattern hair loss, baldness, thinning of hair and may also be associated with skin lesions, scarring. Hereditary factors in combination with male hormones are considered to influence male-pattern hair loss.The term “drug induced hair loss,” as used herein, refers to any drug which is used in another treatment independent of hair root regeneration treatment. Such treatments may include cancer treatment with chemotherapy. Chemotherapeutic drugs are known in the art to cause hair thinning or hair loss leading to baldness.
[0084] The term “autoimmune diseases” is well-known in the art and refers for example to systemic lupus erythematosus (SLE), discoid lupus erythematosus (DLE), dermatomyositis (DM), scleroderma and rheumatoid arthritis (RA). Alopecia areata is also a form of autoimmune disease.
[0085] In an alternative preferred embodiment of the above preferred embodiment, the damaged hair root and / or hair loss associated with alopecia is caused by hereditary factors.
[0086] As regards the embodiments characterized in this specification, in particular in the claims, it is intended that each embodiment mentioned in a dependent claim is combined with each embodiment of each claim (independent or dependent) said dependent claim depends on. For example, in case of an independent claim 1 reciting 3 alternatives A, B and C, a dependent claim 2 reciting 3 alternatives D, E and F and a claim 3 depending from claims 1 and 2 and reciting 3 alternatives G, H and I, it is to be understood that the specification unambiguously discloses embodiments corresponding to combinations A, D, G; A, D, H; A, D, I; A, E, G; A, E, H; A, E, I; A, F, G; A, F, H; A, F, I; B, D, G; B, D, H; B, D, I; B, E, G; B, E, H; B, E, I; B, F, G; B, F, H; B, F, I; C, D, G; C, D, H; C, D, I; C, E, G; C, E, H; C, E, I; C, F, G; C, F, H; C, F, I, unless specifically mentioned otherwise.
[0087] Similarly, and also in those cases where independent and / or dependent claims do not recite alternatives, it is understood that if dependent claims refer back to a plurality of preceding claims, any combination of subject-matter covered thereby is considered to be explicitly disclosed. For example, in case of an independent claim 1 , a dependent claim 2 referring back to claim 1 , and a dependent claim 3 referring back to both claims 2 and 1 , it follows that the combination of the subject-matter of claims 3 and 1 is clearly and unambiguously disclosed as is the combination of the subject-matter of claims 3, 2 and 1. In case a further dependent claim 4 is present which refers to any one of claims 1 to 3, it follows that the combination of the subject-matter of claims 4 and 1 , of claims 4, 2 and 1 , of claims 4, 3 and 1 , as well as of claims 4, 3, 2 and 1 is clearly and unambiguously disclosed.
[0088] The Figures show:
[0089] Fig. 1: Preliminary experiments for the determination of the concentrations for A) the growth medium and B) the compounds. A) Determination of the optimal growth conditions. The basal medium (Follicle Dermal Papilla Cell Growth Medium, Promo Cell, Heidelberg, Germany) has been supplemented with different amounts of fetal calf serum (FCS) prepared in dilutions of 0%, 0,1%, 1%, 2%, 4%, 10%. No significant difference between 1%, 4%, 8% or 10% is observable. For further experiments 4% supplementation is used, in accordance with the manufacturer’s concentration. B) Determination of optimal concentrations of different compounds. Dilutions of lO mM, 1 mM, 100 pM, 10pM, 1 pM, 100 nM, 10 nM, and 1 nM of each of caffeine, minoxidil, finasteride and dilutions of concentrations of 40%, 30%, 20%, 10%, 5%, 2%, 1% of each of hypoxia preconditioned serum (HPS) and platelet-rich plasma (PRP) are compared. The fluorescence using a MITRAS Reader (Berthold Technologies) is depicted, wherein the best value is indicated with a dark green color and an arrow The optimal concentrations determined are caffeine 10 pM, minoxidil 1 mM, finasteride 10 mM, PRP 40%, HPS 1%.
[0090] Fig. 2 Microscopic analysis of cell proliferation and migration of cells under different conditions.
[0091] Cells were seeded under conditions as determined in Example 1. The wells, each containing one sphere, were separated into 12 groups: positive control (medium + supplement mix)), negative control (DMEM), minoxidil, caffeine, finasteride, PRP LD, PRP HD, HPS LD, HPS HD, NS LD, NS HD (NS = normal serum, HD = High Dose = 40%, LD = Low Dose = 1%) wherein each group has been prepared in 3 replicates. Solutions of each compound and simultaneously 5-ethynyl 2’-desoxyuridine (EdU) has been added.
[0092] The effect of the compounds was measured for 48h, while the plates containing cell spheres were conditioned at 37°C in a damped atmosphere with 5% CO2. A) Images of incorporated uracil bases in proliferating daughter cells. Upper left: brightfield (BF), upper right: EdU, lower left and lower right: DAPL Overlay images of compounds of the experiment as described are provided for better visualization. Migration of cells (distance and area of migrating cells) that have been treated with HPS or PRP are significantly increased compared to the drug approaches. Scale bars are 1,000 pm. B) Image analysis and statistics. The graph shows the ratio of EdU-positive cells vs. all cells in each of the indicated conditions from which the proliferation and survival of the cells is derivable. indicates the negative control, “+” indicates the positive control. The statistical significance is demonstrated under consideration of the positive control and demonstrated according to the symbols: * low significance, ** medium significance, *** high significance, **** very high significance. A significantly higher proliferation of cells treated with HPS and PRP in comparison to commercially available medications is observable. PRP demonstrated a higher stimulating effect on cell proliferation than HPS, wherein the cell proliferation stimulating effect is dose dependent.
[0093] Fig. 3 Gene expression analysis using qPCR. Supernatant of the cells cultured and treated as described in Fig. 2 has been used for gene expression analysis. Hair growth associated genes ALP, IGF-1 , versican, SRD5A1 , SRD5A2, SRD5A3, KGF, VEGF-A, EGF, TSP-1 , PF-4 were studied fortheir gene expression levels in the supernatant of treated cells in real time for phenotype analysis. Two technical replicates were analyzed in qPCR, wherein GAPDH has been used as house-keeping gene for standardization. SRD5A1-A3 encode androgyne receptors, versican is associated with hair morphogenesis, ALP (alkaline phosphatase) expression varies in a hair cycle. IGF1 (insulin-like growth factor 1) stimulated the hair cycle, Kgf, VEGF, EGF, TSP1 , PF4 are growth factors associated with hair growth. Treatment with HPS in low as well as high doses in dependence on the specific gene (e.g., versican and VEGFa), results in an increase of gene expression, which is higher than that after PRP treatment.Fig. 4: Relative absorption of cells treated with secretomes. The relative absorption of cells cultured with Alamar Blue increases with higher concentrations of the various sera (PRP: red, HPS: turquoise, NS: red). All sera show the highest growth at a 40% concentration. Differences in growth are observed at low concentrations.
[0094] Fig. 5: Spheroid migration-assay of daughter cells of human dermal hair follicle cells. A.
[0095] Treatment with secretomes from autologous blood for 48 hours. Higher concentrations of NS, HPS, and PRP result in further peripheral migration of HFDPCs in 3D spheroid culture after 48 hours. Lower concentrations were also able to stimulate migration, though to a lesser extent. The strong migrationpromoting effect of PRP at both high and low doses is worth noting. B. Treatment with well-known hairloss drugs for 48 hours. The drugs do not have a statistically significant positive effect on the migration of daughter cells.
[0096] Fig. 6: Proliferation of human dermal papilla cells - EdU incorporation assay. A. Treatment with autologous blood secretomes for 48 hours. Higher concentrations of all sera result in increased proliferation of HFDPCs in 3D spheroid culture after 48 hours. Representative images of daughter cell production following 48 hours of culture with the respective serum show high proliferation activity at high serum concentrations. Lower concentrations were also able to stimulate daughter cell production, though not to the same extent. B. Treatment with well-known hair-loss drugs for 48 hours. Finasteride and caffeine increase the rate of cell division, whereas minoxidil does not have a significant positive effect on cell proliferation. The images show lower production of new cells compared to the serums.
[0097] Fig. 7: RNA sequencing of cells. A. Heatmap of Iog2 fold changes of 2120 differentially expressed genes (p>0.05, log2FC >2). Rows = genes (clustered using Euclidean distance k-means clustering), columns = treatment groups (N = 24, 3 biological replicates per condition). Colors represent log2fold changes relative to the reference condition: blue = downregulated, red = upregulated. Scale range: -4 to +4 (adjusted to fit the data). The exact color gradient is shown in the color bar on the right. There is a strong clustering pattern among the individual conditions. HPS 40 and NS40 show a strong effect on gene expression. B. Number of up-regulated and down-regulated genes per condition compared to the respective control groups. The bar chart summarizes the results of the differential gene expression analysis (DESeq2 I edgeR; Wald test, Benjamini-Hochberg-corrected p < 0.05, absolute log2fold change > 2). Each bar represents a pairwise comparison between a treatment condition and the corresponding control group. HPS 40% shows the strongest transcriptional response (vs. positive control and vs. negative control), with >1 ,000 differentially expressed genes in each case. All serumbased high-concentration conditions (HPS 40%, NS 40%, PRP 40%) induce a significantly higher number of regulated genes than low-dose growth factors / regimens (HPS 1 %, NS 1 %, PRP 1 %) or over-the-counter (OTC) medications, indicating a stronger biological effect of the sera at the cellular level.
[0098] Fig. 8: Comparative gene expression analysis of PRP40 vs. positive control (38 differentially expressed genes). A. Heatmap of the row-centered and scaled (z-score-normalized) expression values for the 38 genes. Rows = genes, hierarchically clustered (Euclidean distance, complete linkage).Columns = individual samples, grouped by treatment condition (PRP 40% replicates, positive control). Color scale (to the right of the heatmap): blue = below-average expression (z < 0), red = above-average expression (z > 0), relative to the respective gene mean. The heatmap shows that only a very small number of genes (n = 38) exhibit significantly different expression levels between PRP40 and the positive control — in contrast to the much stronger effects observed with HPS40 or other sera (see Fig.
[0099] 4.2). Most of these genes exhibit moderate fold changes (± 1 to ~4), and the samples within the PRP40 group cluster closely together, indicating a consistent but weak transcriptional response. B. Volcano plot of differential expression (PRP40 vs. positive control), x-axis: log2fold change (positive = higher in PRP40, negative = higher in positive control). Y-axis: -loglo(adjusted p-value). Plots: black / gray = not significant, red = significant according to adjusted p-value and log2FC criteria, gray with black border = significant only according to nominal p-value. Selected genes with strong regulation are labeled (e.g., MATN2, HDAC2, LINC00607, CA1 , SLC4A1 , NFKB2, CXCL5, FND3C1). Dotted lines mark the significance thresholds. The Volcano plot confirms the results of the heat map: very few genes achieve both high statistical significance and strong regulation. Genes such as NFKB2, CXCL5, SLC4A1 , CA1, or HDAC2 show partially opposing patterns of regulation (higher in the positive control or higher in PRP40), but overall point to a minimal immunomodulatory or inflammation-associated response. C.
[0100] Gene Ontology (GO) enrichment analysis (Biological Process) for differentially expressed genes (PRP40 vs. positive control). Bubble plot: x-axis = gene ratio (proportion of associated genes in the GO term), y-axis = adjusted p-value (-loglo). The only significantly enriched term (adj. p < 0.05): “spleen development” (G0:0048536), highlighted by color and size. The GO enrichment analysis yields only a single weakly but significantly enriched biological process term: “spleen development” (G0:0048536). This term describes processes of spleen development (including lymphoid organogenesis, B- and T-cell maturation in the spleen, and the formation of the white and red pulp). However, the enrichment is very weak (gene ratio ~0.06-0.14, adj. p at the threshold), is based on only a few genes, and should therefore be interpreted with caution — it suggests a minimal, nonspecific overlap with developmental / differentiation processes rather than a biologically dominant effect.
[0101] Fig. 9: Comparative gene expression analysis of NS40 vs. positive control (305 differentially expressed genes). A. Heatmap of the row-wise z-score-normalized expression values for the 305 genes. Rows = genes (hierarchically clustered: Euclidean distance, complete linkage). Columns = samples, grouped by condition (NS40 replicates, NS replicates, positive control). Color scale: blue = below average (z < 0), red = above average (z > 0) relative to the gene mean. Top annotation: groups (NS40, NS, positive control). B. Volcano plot (NS40 vs. positive control), x-axis: log2fold change (positive = higher in NS40, negative = higher in positive control), y-axis: -loglo(adjusted p-value). Points: gray / black = not significant, red = significant (adj. p + |log2FC|), gray with border = only nominally significant. Highlighted genes: e.g., CXCL5, CXCL3, NFKB2, CCL20, HTR3B, EM CN, MYO9B, SDC4, RAM, PLXDC. Dotted lines = significance thresholds. C. GO enrichment (Biological Process) for DEGs (NS40 vs. positive control). Bubble plot: x = GeneRatio, y = -loglo(adjusted p), bubble size = number of genes (count). Highly enriched terms (adj. p < 0.05): response to molecule of bacterial origin I lipopolysaccharide (LPS), canonical NF-KB signal transduction, cellular response to biotic stimulus, regulation of epithelial cell proliferation, ERK1 / ERK2 cascade, response to nutrient, cell differentiation,negative regulation of fatty acid oxidation, etc. Color gradient based on adjusted p-value (red = highly significant). NS40 induces a moderate but distinct transcriptional response involving 305 differentially expressed genes. The volcano plot shows a number of highly significant chemokines and inflammatory mediators (e.g., CXCL5, CXCL3, CCL20, NFKB2) that are predominantly upregulated in NS40. GO enrichment highlights strong themes related to the innate immune response: response to bacterial LPS / bacterial molecules, canonical NF-KB signaling pathway, ERK1 / 2 cascade, regulation of epithelial and smooth muscle cell proliferation, and cell migration. Overall, NS 40% exhibits a focused, pro-inflammatory, and growth-stimulating signature, which is, however, significantly weaker than in HPS 40%.
[0102] Fig. 10: Comparative gene expression analysis of NS40 vs. positive control (305 differentially expressed genes). A. Heatmap of the row-wise z-score-normalized expression values for the 1 ,262 genes. Rows = Genes (hierarchically clustered). Columns = Samples (HPS40 replicates, HPS replicates, positive control). Color scale: blue —> red (as above). Clear separation of the groups, strong up- and down-regulation in HPS40. B. Volcano plot (HPS40 vs. positive control). X-axis: log2fold change (extreme range up to +15 / -10). Y-axis: -loglo(adj. p) up to >40 —> extremely high significance. Many highly significant points (red), strong regulation. Highlighted genes: CXCL5, CXCL3, CCL20, TNF, TRAF1 , NFKB, SDC4, CXCL2, CCL3, IL1B, MMP9, SOX9, DK K1 , PLXDC1 , MATN2, etc. - clear pro-inflammatory / chemotactic signature. C. GO enrichment (Biological Process). Bubble plot (as above). Highly enriched terms (adj. p « 0.05, high counts): response to molecule of bacterial origin I lipopolysaccharide (LPS), response to hypoxia I decreased oxygen levels, extracellular matrix organization I structure development, response to biotic stimulus, renal I kidney development, vasculature development, muscle cell proliferation I migration, cellular response to toxin I lipopolysaccharide, etc. Very broad spectrum of inflammatory, hypoxia, and tissue remodeling processes. HPS 40% triggers by far the strongest transcriptional reprogramming (1262 DEGs). The Volcano plot shows extremely high fold changes (up to +15) and very high statistical significance (-loglop > 40), with massive induction of pro-inflammatory chemokines (CXCL5, CXCL3, CXCL2, CCL3, CCL20), cytokines (TNF, IL1B), and matrix remodeling genes. The GO enrichment is broad and highly significant: Response to LPS I bacterial molecules, Hypoxia response, Extracellular matrix organization, Vascular and renal development, Muscle cell proliferation / migration, and Toxin response. HPS40 mediates an intense, broad-spectrum inflammatory, hypoxic, and tissue-remodeling signature — biologically the most potent of the three tested preparations.
[0103] Fig. 11: RNA sequencing of cells - analysis of target genes. A. HIF1A Target gene expression. B.
[0104] Key HIF1A target genes. C. Top 50 variable transcription factor (TF) activities. D. HIF-related and proliferation TF activities. E. TF activities: 40% conditions vs positive control. F. TF activity changes vs. positive control.
[0105] Fig. 12: RNA sequencing of cells - HPS40 leads to significant increase in transcription factor activation compared to NS40 and PRP40. A. TF activity changes vs. positive control of HPS40, NS40 and PRP40. B. TF activity changes: HPS40 vs. positive control. C-D. TG activity changes vs. positivecontrol; size = magnitude of effect, opacity = significance. E-G. TF activity changes vs. positive control in different diagrams.
[0106] The invention is illustrated by the examples.
[0107] Example 1
[0108] Material and Methods.
[0109] Cell Culture
[0110] HF-DPCs (human follicle dermal papilla cells) were purchased from Sigma-Aldrich and cultured in Follicle Dermal Papilla Cell Growth Medium (Promo Cell, Heidelberg, Germany) supplemented with “supplement mix for Follicle Dermal Papilla Cell Growth Medium” and 1% antibiotics / antimycotics (penicillin G, streptomycin and amphotericin C) (Capricorn Scientific). The cell culture medium was exchanged every 2 days and the cells splitted upon reaching an 80-90% confluency with 0.25 / 0.02% trypsin / EDTA (PAN Biotech). All cells were conditioned at 37°C in a damped atmosphere with 5% CO2. The cells were used subsequently after splitting and were not cultured beyond a passage of 4.
[0111] Preliminary experiment 1 : Growth media concentration determination
[0112] After washing and counting of the cells, 5000 cells per well seeded in 96-Well PrimeSurface® 3D Culture Spheroid: Ultra-low Attachment (ULA) plates (S-Bio, USA). 3 technical replicates were performed. The basal medium (Follicle Dermal Papilla Cell Growth Medium, Promo Cell, Heidelberg, Germany) has been supplemented with different amounts of Fetal Calf Serum prepared in dilutions of 0%, 0,1%, 1%, 2%, 4%, 10%. The cells have been incubated for48h (37°C, 4% CO2). No significant difference between 1%, 4%, 8% or 10% is observable (Fig. 1 A). For further experiments 4% supplementation is used, in accordance with the manufacturer’s concentration.
[0113] Preliminary experiment 2: optimal concentration of compounds
[0114] To determine the optimal compound concentrations of each of the compound’s dilutions of 10 mM, 1 mM, 100 pM, 10 pM, 1 pM, 100 nM, 10 nM, and 1 nM of each of caffeine, minoxidil, finasteride, and dilutions of concentrations of 40%, 30%, 20%, 10%, 5%, 2%, 1% of each of hypoxia preconditioned serum (HPS) and platelet-rich plasma (PRP) have been prepared. Basal medium as used in A supplemented with 4% FCS has been used to culture cells (37 °C, 4 % CO2) for 48 h. 100 pL of Alamarblue (10%) was added to the cells, which were subsequently incubated for another 24h before measuring the fluorescence using a MITRAS Reader (Berthold Technologies). The optimal concentrations determined are caffeine 10 pM, minoxidil 1 mM, finasteride 10 mM, PRP 40%, HPS 1%. For further experiments the herein determined concentrations were applied. Caffeine solution was prepared by diluting 1 g caffeine in 50 mL ddH2O to obtain a 100 mM caffeine stock solution, which was diluted by 1 :1000 in basal medium to obtain a caffeine solution, followed by 1 :10 dilution in the basal medium as working solution (10 pM). Minoxidil stock solution (100 mM) was prepared by dissolving 104 mg of minoxidil in 5 mL ddH2O and diluted in 1 :100 in medium for obtaining the working solution.Finasteride stock solution of 1 M was prepared by solving 100 mg finasteride in 270 mL DMSO, while said stock solution was used with 1 :100 dilution in basal medium. PRP solution was 800 pL PRP on 1120 pL medium, while HPS 1% was prepared with 20 pL HPS and 1980 pL medium and HPS10 % was prepared with 200 pL HPS and 1800 pL medium.
[0115] Spheroid culture:
[0116] After washing and counting of the cells, 5000 cells per well seeded in 96-Well PrimeSurface® 3D Culture Spheroid: Ultra-low Attachment (ULA) plates (S-Bio, USA). The cells were cultured in 100 pL of Follicle Dermal Papilla Cell Growth Medium supplemented with 4% FCS as determined in the preliminary experiments. The plates were incubated for48h to ensure the formation of stable spheres.
[0117] Staining and compound dosage / concentration:
[0118] The cell spheres were transferred to FlatBottom plates using a 200 pL pipet. Each well contained 1 sphere. The wells were separated in 12 groups: positive control (medium + supplement mix)), negative control (DMEM), minoxidil, caffeine, finasteride, PRP1%, PRP40%, HPS1%, HPS40%, wherein each group has been prepared in 3 replicates. Solutions of each compound has been prepared which provide the doubled % of weight percent of the future condition. The spheres in 100 pL of culture medium were treated with 100 pL of the solutions of each compound and simultaneously with 5-ethynyl 2’-desoxyuridine (EdU). The EdU solution has been added separately, not together with the compound solutions. The effect of the compounds was measured for 48h, while the plates where conditioned at 37°C in a damped atmosphere with 5% CO2. At the end of the test phase supernatant was collected using a 100 pL pipet and used for PCR. Cells were fixed with aldehyde according to the manufacturer’s instructions and prepared for brightfield and fluorescence microscopy (ZEISS, Oberkochen, Germany) by staining with DAPI after concluding the EdU staining. The latter is used to image the incorporated base in proliferating daughter cells. The experiment was conducted with 3 biological replicates seguentially.
[0119] Image analysis and statistics:
[0120] The guantified green fluorescence and the area of migration of the spheroid cells were analyzed using Imaged (NIH) and IKOSA (KML version). Each group comprises 3 technical replicated of 3 biological replicates (n=3). Two tailed students’ t-test was used for direct comparison of two groups. A p-value of p<0.05 is considered statistically significant. The data is depicted as mean ± SD. All statistical analysis were performed with GraphPad Prism software (GraphPad Software Inc., La Jolla, CA, USA, http: / / www.graphpad.com).
[0121] Gene expression gPCR:
[0122] The gene expression of genes associated with hair growth ALP, IGF-1 , versican, SRD5A1 , SRD5A2, SRD5A3, KGF, VEGF-A, EGF, TSP-1 , PF-4 was assessed with guantitative reverse-transcriptions-polymerase-chain reaction (RT-gPCR) in real time for phenotype analysis. Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was used as reference house-keeping gene for all gene expression analyses. After cell culture time, samples were lysed with buffer RLT lysis buffer (QIAGENGmbH, Hilden, Germany) and stored at -80°C until further processing. The RNase Mini Kit (QIAGEN GmbH, Hilden, Germany) was used for extraction of the whole cell RNA according to the manufacturer’s instructions. The purity and concentration of the RNA was determined using a NanoDrop spectrometer (Implen GmbH, Munich, Germany). The reverse transcription of the RNA samples was conducted using the SensiFast cDNA synthesis kit (Meridian Bioscience, Cincinnati, OH, USA) according to the Manufacturer’s instructions with 500 ng whole cell RNA. The produced cDNA was used as triple sample for RT-PCR reactions, wherein primers were used that cover exon-exon-borders, to ensure a cDNA specific amplification. The qPCR was performed using the NoROX SYBR MasterMix bleu dTTP (Eurogentec, Luttich, Belgium). The sample was mixed with the PCR-Mastermix and the gene specific primer mix in a 384-well plate (Fisher Scientific, Waltham, MA, USA) in a final primer concentration of 100 nM. The plate was sealed and mixed by vortexing, followed by a centrifugation at 2000*g for 5 minutes at 4°C.
[0123] Example 2: Migration and Proliferation studies
[0124] Spheroid cultures were prepared as described above under the conditions to be studied (different concentrations of compound treatment). The cells were simultaneously treated with EdU solution to stain uracil bases in proliferating cells. After treatment, the cells were fixed and stained with DAPI to visualize the nucleus and imaged in fluorescence and brightfield microscopy. Fig. 2A shows images of cells treated with high or low doses of HPS or PRP or the commercially available compounds in the concentrations as determined in Fig. 1B (preliminary experiment 2). Fig. 2B shows selected images of cells treated with PRP or caffeine, wherein the different fluorescence planes were overlayed for improved visualization. Cells treated with HPS or PRP migrate further and in higher numbers of cells in comparison to those cell spheres treated with commercially available compounds.
[0125] The green fluorescence of the EdU staining was quantified and is graphically depicted in Fig. 2C. The quantification indicated proliferation and survival of cells treated with different conditions. The conditions HPS40 (high dose HPS, 40% concentration), HPS1 (low dose HPS, 1% concentration), PRP40 (high dose PRP, 40% concentration), PRP1 (low dose PRP, 1% concentration), caffeine, finasteride, minoxidil were subtracted by the values obtained for the positive control (“+”; medium + supplement mix) and negative control (“-“; medium only). The treatment with HPS and PRP was compared to caffeine treated cells (comparison standard). Caffeine and finasteride treatment achieved a similar ratio of EdU positive cells, while minoxidil treatment resulted in the lowest number of proliferating cells. High doses of HPS and PRP achieved a very high significant increase in the number of EdU positive (proliferating) cells, while low doses resulted in slightly lower levels with a high significant difference to the comparison standard. The results indicate that the blood derived secretomes (HPS / PRP) are superior in stimulating cell proliferation compared to the drug approaches.
[0126] Example 3: Gene expression by qPCR
[0127] Gene expression of ALP, IGF-1 , versican, SRD5A1 , SRD5A2, SRD5A3, KGf7, VEGFa, EGF, TSP1 , PF4 in comparison to GAPDH as reference house-keeping gene (standard) was assessed with quantitative reverse-transcriptions-polymerase-chain reaction (RT-qPCR) as described above. The two replicates are depicted in each graph in Fig. 3, wherein in each graph low doses of 1% HPS and PRPand high doses of 40% HPS and PRP have been used. SRD5A1-A3 encode androgyne receptors, versican is associated with hair morphogenesis, ALP (alkaline phosphatase) expression varies in a hair cycle. IGF1 (insulin-like growth factor 1) stimulated the hair cycle, KGf7, VEGFa, EGF, TSP1 , PF4 are growth factors associated with hair growth. It is noticeable that some genes result in increased expression with high doses of HPS or PRP, while others prefer low doses of HPS or PRP, wherein HPS shows a higher gene expression for genes such as versican and VEGFa while PRP does not.
[0128] The increase of the gene expression of hair growth or morphogenesis associated genes in HPS treated cells indicates the positive effect of factors comprised in the composition of the present invention on hair root regeneration and hair growth.
[0129] Example 4: Evaluation of migration and proliferation.
[0130] To evaluate the proliferative potential of the sera, first a series of dilutions with increasing concentrations were conducted. For this purpose, the cells (HF-DPCs) were incubated with Alamar Blue for 48 hours. After the incubation period, the proliferative capacity / viability was evaluated by measuring the relative absorbance (c.f., Figure 4).
[0131] To evaluate the effect of the various sera on the cells’ proliferative capacity, the cells were examined using fluorescence microscopy. Two parameters were assessed: the migration of the cells from the initial 3D culture and the cells’ ability to divide. Proliferation was assessed using 5-ethynyl-2'-deoxyuridine (Edll) labeling. This thymidine analog is incorporated into dividing cells, allowing for permanent labeling of the cells. The cells that incorporated Edll into their DNA had accordingly divided during the incubation period (c.f., Figures 5 and 6).
[0132] Example 5: RNA-Sequencinq
[0133] RNA sequencing was performed to evaluate the complex effects of sera on the cells (HF-DPCs). As in previous experiments, a 3D spheroid was created and then cultured in the presence of various sera. The RNA from the cells was subsequently isolated and sequenced. RNA sequencing allows for the precise investigation of multifactorial processes in cells, thereby distinguishing itself from techniques that measure only specific parameters. By analyzing all genes in a cell, conclusions can be drawn about many cellular parameters, including division rates, signaling processes, immune responses, and stress signals. To identify relevant factors, the data were analyzed using the “DESeq2” package, which is considered the gold standard. This allows for the identification of significantly differentially regulated genes through statistical models (c.f., Figures 7 to 10). The results indicate that all tested sera have an activating effect on tested transcription factors, with HPS40 showing the most potent effect. Hypoxia and proliferation-pathways are particularly targeted by HPS40.
[0134] The gene expression data shown in Figure 7 reveal a clear link to hypoxic conditioning of HPS.
[0135] Figure 10 (HPS40 vs. Positive Control, 1262 DEGs): The strong GO enrichment for “response to hypoxia I decreased oxygen levels” (high GeneRatio, adj. p « 0.05, large bubble size) underscores the central role of hypoxia. This suggests that HPS40 activates hypoxia-associated pathways in the treated cells, e.g., via HIF-1a, leading to massive upregulation of genes such as CXCL5, CXCL3, TNF, IL1B, and MMP9. These genes are typical of hypoxic stress responses: they promote angiogenesis (VEGFpathways), inflammation (chemokines), and tissue remodeling (ECM organization, as seen in GO terms). The extremely high fold changes (up to +15) and significance levels (-loglop > 40) reflect the hypoxia-induced secretion of regenerative factors that are enriched in HPS — resulting in broad, potentially therapeutic cell activation (e.g., for wound healing or hypoxia-resistant tissues). Compared to NS40 (Figure 9), the hypoxia response here is more intense and broader, which is attributable to the higher dose (40%) and hypoxic preconditioning.
[0136] It should be noted that the inflammatory response is a potentially undesirable reaction. Since both normal serum and hypoxic serum upregulate these genes, it stands to reason that these genes may have been triggered by donor-specific contamination.
[0137] Comparison to other panels: NS 40% (305 DEGs) shows a less prominent hypoxia response (GO focus on LPS / NF-KB, without strong hypoxia enrichment), as NS does not undergo hypoxic preconditioning. PRP 40% (only 38 DEGs) shows no significant hypoxia-related signature at all (only a weak “spleen development” term), which identifies PRP as a “milder” preparation without hypoxic potentiation.
[0138] Overall, the data confirm that hypoxia in HPS maximizes transcriptional potency: HPS40 induces a hypoxia-mimetic protective response that makes cells more resilient and accelerates regeneration — an advantage over NS or PRP.
[0139] References
[0140] Alkilani, A. Z., McCrudden, M. T., & Donnelly, R. F. (2015). Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum. Pharmaceutics, 7(4), 438-470.
[0141] Cao L, Mooney DJ (2007) Spatiotemporal control over growth factor signaling for therapeutic neovascularization. Adv Drug Deliv Rev 59:1340-1350
[0142] Cheema U, Brown RA, Alp B, MacRobert AJ (2008) Spatially defined oxygen gradients and vascular endothelial growth factor expression in an engineered 3D cell model. Cellular and Molecular Life Sciences 65:177-186
[0143] Di SS, Yang Z, Wyler von BM, Voelzmann J, Diehm N, Baumgartner I, Kalka C (2009) Novel cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned medium can replace progenitor cell transplantation. PLoS One 4:e5643
[0144] Hadjipanayi E, Brown RA, Mudera V, Deng D, Liu W, Cheema U (2010b) Controlling physiological angiogenesis by hypoxia-induced signaling. J Control Release 146:309-317
[0145] Hadjipanayi E, Cheema U, Mudera V, Deng D, Liu W, Brown RA (2011) First implantable device for hypoxia-mediated angiogenic induction. J Control Release 153:217-224
[0146] Ji, S., Zhu, Z., Sun, X. et al. Functional hair follicle regeneration: an updated review. Sig Transduct Target Ther 6, 66 (2021). https: / / doi.org / 10.1038 / s41392-020-00441-y
[0147] Kubo M, Li TS, Kamota T, Ohshima M, Qin SL, Hamano K (2009) Increased expression of CXCR4 and integrin alphaM in hypoxia-preconditioned cells contributes to improved cell retention and angiogenic potency. J Cell Physiol 220:508-514
[0148] Namiki A, Brogi E, Kearney M, Kim EA, Wu TG, Couffinhal T, Varticovski L, Isner JM (1995) Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. Journal of Biological Chemistry 270:31189-31195Pratt C.H., King Jr, L.E., Messenger, A G., Christiano, A. M., Sundberg J. P. (2017) Alopecia areata. Nat Rev Dis Primers. 3;17011. Doi:10.1038 / nrdp.2017.11.
[0149] Triieb, R. M. (2015) The impact of oxidative stress on hair. Int. J. Cosmet. Sci. 37(Suppl 2), 25-30. Triieb. R. M. (2021), Oxidative stress and its impact on skin, scalp and hair. Int J Cosmet Sci.
[0150] 2021 ;43(Suppl. 1):9-13.
[0151] Shimizu, Y., E. H., Ntege, H. Sunami, Y. Inoue. (2022) Regenerative medicine strategies for hair growth and regeneration: A narrative review of literature. Regenerative Therapy. 21 : 527-539.
[0152] Jiang, J., Altammar, J., Cong, X., Ramsauer, L., Steinbacher, V., Dornseifer, U., ... & Moog, P. (2023). Hypoxia preconditioned serum (HPS) promotes proliferation and chondrogenic phenotype of chondrocytes in vitro. International Journal of Molecular Sciences, 24(13), 10441.
[0153] Jiang, J., Cong, X., Alageel, S., Dornseifer, U., Schilling, A. F., Hadjipanayi, E., ... & Moog, P. (2023). In vitro comparison of lymphangiogenic potential of hypoxia preconditioned serum (HPS) and platelet-rich plasma (PRP). International Journal of Molecular Sciences, 24(3), 1961.
Claims
26Claims1. A composition for use in a method of regenerating damaged hair roots and / or reverting hair loss comprising factors obtained or obtainable by a method comprising or consisting of(a) subjecting cells to stress; and(b) collecting the supernatant comprising factors produced by said cells when subjected to said stress under conditions that prevent contamination of said supernatant by pathogens and / or non-pathologic cells and / or parts of pathogens or non-pathogenic cells; andthereby obtaining said composition.
2. The composition for use of claim 1 , wherein the subjecting to stress is effected by exposing said cells to(i) hypoxia;(ii) mechanical stress; and / or(iii) electric stimulation.
3. The composition for use of claim 1 or 2, wherein the cells are blood cells or adipose tissue-derived stromal cells.
4. The composition for use of claim 1 or 2, wherein said cells are autologous, allogeneic or xenogeneic(iv) fibroblasts; bone-marrow derived stromal cells; skeletal, smooth or cardiac muscle cells; epithelial cells; or adult stem cells;(v) myoblasts; osteocytes; osteoblasts; osteoclasts; chondrocytes; skeletal, smooth or cardiac muscle cells; dermal, tendon or cardiac fibroblasts; endothelial cells; or adult stem cells, or(vi) nerve cells; glial cells; skeletal, smooth or cardiac muscle cells; fibroblasts; osteocytes; osteoblasts; osteoclasts; chondrocytes; or adult stem cells including neural stem cells.
5. The composition for use of any one of claims 1 to 4, wherein said cells are comprised in at least one first carrier and said collecting is effected by means of a second carrier which at least one second carrier is concomitantly present with and spatially distinct from the first carrier(s); and wherein first carrier and second carrier are positioned such that factors secreted by said cells when subjected to stress are collected in said second carrier,wherein at least one filter is positioned between said first and second carrier which prevents any cells or parts of cells and pathogens present in (any of) said first carrier(s) from entering into said second carrier.
6. The composition for use of any one of claims 1 to 5, wherein step (a) or step (b) are repeated two or more times.
7. The composition for use of any one of claims 1 to 6, wherein the cells are mammalian cells.
8. The composition for use of claim 7, wherein the mammalian cells are human or porcine cells.
9. The composition for use of any one of claims 1 to 8, further comprising erythropoietin (EPO).
10. The composition for use of any one of claims 1 to 9, wherein the regeneration of damaged hair roots is a therapeutical regeneration.
11. The composition for use of any one of claims 1 to 10, wherein the regeneration of damaged hair roots is a cosmetic regeneration.
12. Use of a composition as defined in any one of claims 1 to 9 for cosmetic regeneration of damaged hair roots.
13. The composition for use of any one of claims 1 to 11 or the use of claim 12, wherein the composition is to be administered topically or transdermally to a subject in a therapeutically or cosmetically effective amount.
14. The composition for use of claim 13, wherein the therapeutically effective amount to be administered is between 1% and 40%, preferably about 40%.
15. The composition for use of claim 13 or the use of claim 12, wherein the cosmetically effective amount to be administered is between 1% and 40%, preferably about 40%.
16. The composition for use of any one of claims 1 to 10, 13 and 14, wherein the damaged hair root and / or hair loss is associated with alopecia; physical or psychological stress; hormonal dysfunctions or alterations; infectious diseases; medication induced; drug induced hair loss; and / or autoimmune diseases.
